Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts for review Imbruvica submission for Waldenstrom's macroglobulinemia

Dec. 1, 2014

LCZ-696 granted accelerated assessment by CHMP in Europe

Dec. 1, 2014

Ocata granted European ATMP designation for RPE program for macular degeneration

Nov. 26, 2014

ATX-F8-117 receives European orphan medicinal product designation for hemophilia A

Nov. 26, 2014

Vorapaxar receives positive opinion from EMA

Nov. 25, 2014

EMA committee recommends approval of Travatan for use in pediatric patients

Nov. 25, 2014

CHMP recommends granting marketing authorization for Shionogi's Senshio

Nov. 25, 2014

EMA issues new recommendations for the use of Corlentor/Procoralan

Nov. 25, 2014

CHMP backs Otezla for psoriasis and psoriatic arthritis

Nov. 24, 2014

CHMP adopts positive opinion for Genzyme's Cerdelga

Nov. 24, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...